Evidence map›Paper›PMID 24676319›Full record

ReviewThe journal of nutrition, health & aging2014

Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

A J Carman, P A Dacks, R F Lane, D W Shineman, H M Fillit

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of nutrition, health & aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05170113 (A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Effectiveness and Safety of an Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health Among Overall Healthy Participants), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05170113 nacompletednot on this mapstarted 2021, after this paper: background citation

A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Effectiveness and Safety of an Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health Among Overall Healthy Participants

TypeinterventionalSponsorSupplement Formulators, Inc.Ran2021 to 2022Enrolled79ConditionsFatigueArmsAlpinia galanga formulation, Theacrine formulation, Caffeine formulation, Placebo
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns About Addiction.International journal of environmental research and public health · 2025
    Review
  8. Review
  9. Review
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Caffeine Protects Against Retinal Inflammation.Frontiers in pharmacology · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Age Modulates the Association of Caffeine Intake With Cognition and With Gray Matter in Elderly Diabetics.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

A J CarmanA.J. Carman, Alzheimer's Drug Discovery Foundation, 57 W. 57th St, Suite 904 NY, NY, USA, acarman@alzdiscovery.org.
P A Dacks
R F Lane
D W Shineman
H M Fillit
Alzheimer's Drug Discovery Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although nothing has been proven conclusively to protect against cognitive aging, Alzheimer's disease or related dementias, decades of research suggest that specific approaches including the consumption of coffee may be effective. While coffee and caffeine are known to enhance short-term memory and cognition, some limited research also suggests that long-term use may protect against cognitive decline or dementia. In vitro and pre-clinical animal models have identified plausible neuroprotective mechanisms of action of both caffeine and other bioactive components of coffee, though epidemiology has produced mixed results. Some studies suggest a protective association while others report no benefit. To our knowledge, no evidence has been gathered from randomized controlled trials. Although moderate consumption of caffeinated coffee is generally safe for healthy people, it may not be for everyone, since comorbidities and personal genetics influence potential benefits and risks. Future studies could include short-term clinical trials with biomarker outcomes to validate findings from pre-clinical models and improved epidemiological studies that incorporate more standardized methods of data collection and analysis. Given the enormous economic and emotional toll threatened by the current epidemic of Alzheimer's disease and other dementias, it is critically important to validate potential prevention strategies such as coffee and caffeine.

Indexed as

AgingAlzheimer DiseaseAnimalsCaffeineCoffeeCognitionCognition DisordersHumansMemory, Short-TermNeuroprotective AgentsPrecision MedicineCaffeineCoffeeNeuroprotective Agents

Identifiers

PMID24676319
PMCPMC12880505
OpenAlexW1981057316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.